about
Viral kinetic modeling: state of the artQuantification of viral infection dynamics in animal experimentsHepatitis C virus-specific cytotoxic T cell response restoration after treatment-induced hepatitis C virus controlDeep sequencing analysis of HCV NS3 resistance-associated variants and mutation linkage in liver transplant recipientsSequential bottlenecks drive viral evolution in early acute hepatitis C virus infection.Improvement of ALT decay kinetics by all-oral HCV treatment: Role of NS5A inhibitors and differences with IFN-based regimens.Using pharmacokinetic and viral kinetic modeling to estimate the antiviral effectiveness of telaprevir, boceprevir, and pegylated interferon during triple therapy in treatment-experienced hepatitis C virus-infected cirrhotic patientsAnalysis of hepatitis C virus decline during treatment with the protease inhibitor danoprevir using a multiscale modelInferring viral dynamics in chronically HCV infected patients from the spatial distribution of infected hepatocytes.Hepatitis C virus RNA elimination and development of resistance in replicon cells treated with BMS-790052Second-phase hepatitis C virus RNA decline during telaprevir-based therapy increases with drug effectiveness: implications for treatment duration.Hepatitis C Viral Kinetics in the Era of Direct Acting Antiviral Agents and IL28B.A method to determine the duration of the eclipse phase for in vitro infection with a highly pathogenic SHIV strain.Characterization of resistance to the nonnucleoside NS5B inhibitor filibuvir in hepatitis C virus-infected patients.Hepatitis C viral kinetics with the nucleoside polymerase inhibitor mericitabine (RG7128)Understanding silibinin's modes of action against HCV using viral kinetic modelingAbundant drug-resistant NS3 mutants detected by deep sequencing in hepatitis C virus-infected patients undergoing NS3 protease inhibitor monotherapyHepatitis C viral kinetics: the past, present, and future.Preclinical evaluation of an anti-HCV miRNA cluster for treatment of HCV infectionEarly dynamics of viremia in patients with genotype 1b chronic hepatitis C: Peg-IFNalpha2a shows earlier viral decline than peg-IFNalpha2b in combination therapy with ribavirin.Persistence of resistant variants in hepatitis C virus-infected patients treated with the NS5A replication complex inhibitor daclatasvir.Mathematical modelling of HCV infection: what can it teach us in the era of direct-acting antiviral agents?Mathematical analysis of multiscale models for hepatitis C virus dynamics under therapy with direct-acting antiviral agents.Dendritic cells in hepatitis C infection: can they (help) win the battle?Drugs in development for chronic hepatitis C: a promising future.Which of our modeling predictions are robust?Interferon-α-induced CD100 on naïve CD8+ T cells enhances antiviral responses to hepatitis C infection through CD72 signal transduction.Daclatasvir + asunaprevir + beclabuvir ± ribavirin for chronic HCV genotype 1-infected treatment-naive patients.Mathematical modeling of multi-drugs therapy: a challenge for determining the optimal combinations of antiviral drugs.On the laws of virus spread through cell populations.3D Spatially Resolved Models of the Intracellular Dynamics of the Hepatitis C Genome Replication Cycle.Comparison of daclatasvir resistance barriers on NS5A from hepatitis C virus genotypes 1 to 6: implications for cross-genotype activity.A pharmacokinetic-viral kinetic model describes the effect of alisporivir as monotherapy or in combination with peg-IFN on hepatitis C virologic response.Understanding the nature of early HCV RNA blips and the use of mathematical modeling of viral kinetics during IFN-based therapy.The impact of fibrosis and steatosis on early viral kinetics in HCV genotype 1-infected patients treated with Peg-IFN-alfa-2a and ribavirin.Drugs in development for viral hepatitis: care and caution.Design evaluation and optimization for models of hepatitis C viral dynamics.Silibinin mode of action against hepatitis C virus: a controversy yet to be resolved.Locking out hepatitis C.Quantitative Analysis of Hepatitis C NS5A Viral Protein Dynamics on the ER Surface.
P2860
Q26824655-18648E7B-5D33-49D8-BD9A-ED9E12F43BBBQ26824804-68065624-8137-47A7-909D-1D9C24B0B925Q28082128-2E84DC12-02D8-4F33-988B-2FE80B1CF134Q28534965-1494149C-1160-487D-A4C2-3E245A8B3E06Q30407004-4747EA73-0C9F-49E0-B694-05240861589CQ33703634-AB02F54A-BAEE-4BA4-AB02-9DD2A67BFDD1Q34057340-284D5491-293F-45E7-9002-87E28424CA60Q34334375-E885456B-B5CC-45F4-B741-6A505173E1D7Q34504820-B9ACA139-EA2D-4799-BE22-99DF7EE4A6EDQ34634791-F0AE9B9A-147F-4737-BB09-74C4BEC97181Q35012057-11A45A08-EC51-4911-8171-466350029F67Q35610571-70699181-B4E6-489A-BCAE-15D5972B56D1Q35633691-2FD1BE51-F88C-40E6-9F42-F4B36759ADBBQ35806182-128B6E02-B77F-43C6-AAD5-A16EDB0417FDQ35878898-22A3F314-0CE0-4993-B4EE-1FC8154A01ACQ35894929-5D282B52-0F04-4C89-99C5-18462D34B024Q36277103-8BFBF090-9854-4207-9A42-9122F367B3E0Q36645517-7C200EBD-5848-4B72-9C46-9DAAC1B402B9Q36659298-D7CAC242-E36B-476B-9E1E-1096682EBB86Q36771385-415FF883-00D7-4677-9113-947FFAD51D95Q36785846-63D6A416-E636-480B-B71E-9F830BBCC248Q36810400-275B139E-DCB5-4DB6-B9F4-A544DF122127Q37138516-A9BC2318-24DE-41C2-8983-068651B7B8C1Q37843841-E88D83CD-F932-487D-AD32-AEB54B60BD0DQ37945270-D8629DCD-0762-420E-B1F4-7D8D9D9F2317Q38030527-6BD4EA57-83BD-40C3-B934-76B1A100DFBDQ40323617-B547B4EC-F240-4DBC-81B0-8D3996AC2E26Q40949225-DAB87F03-B4F9-4505-AB63-9AEC27260F06Q41727459-7323A15D-C1D0-4BB8-B4C5-E3124C67746FQ41754641-7EF459BC-8B67-4F9F-8C5D-E65EAC6548AFQ41925291-E66A8AE7-9E9B-48BA-87B2-2764261C7D60Q42109722-F30C443B-3249-4042-B844-D1B7565B9C79Q42196934-4B0EDABB-3847-4B7B-A579-2A8E603C9F61Q42837685-40A729DA-63DE-480E-9545-07EE674CAB62Q42981009-22539DA9-6746-47BC-92A2-999D18F98760Q43034326-5B1D6019-1EEB-4BC7-8D03-EFF4EA9EFC3AQ43034515-B9700346-EA0A-4B94-94C2-8A6064787A00Q43035431-E853D75B-1BDA-4C97-95C7-D0AB92191CCAQ43036528-F9EEF7CF-C13B-4B98-AA92-3F2AADF7BB1DQ47216796-9043E149-2467-4857-880D-E68274C5AEEC
P2860
description
2010 nî lūn-bûn
@nan
2010 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
A perspective on modelling hepatitis C virus infection.
@ast
A perspective on modelling hepatitis C virus infection.
@en
A perspective on modelling hepatitis C virus infection.
@nl
type
label
A perspective on modelling hepatitis C virus infection.
@ast
A perspective on modelling hepatitis C virus infection.
@en
A perspective on modelling hepatitis C virus infection.
@nl
prefLabel
A perspective on modelling hepatitis C virus infection.
@ast
A perspective on modelling hepatitis C virus infection.
@en
A perspective on modelling hepatitis C virus infection.
@nl
P2093
P2860
P1476
A perspective on modelling hepatitis C virus infection.
@en
P2093
P2860
P304
P356
10.1111/J.1365-2893.2010.01348.X
P577
2010-08-15T00:00:00Z